(S (NP (PRP We)) (VP (VBP propose) (NP (NP (DT a) (JJ hybrid) (JJ sequential) (NN deep) (VBG learning) (NN model)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP AMD) (NN progression)) (PP (IN in) (NP (JJ non-exudative) (NNP AMD) (NNS eyes)))))) (PP (IN at) (NP (JJ multiple) (NNS timepoints))) (, ,) (S (VP (VBG starting) (PP (PP (IN from) (NP (NP (JJ short-term) (NN progression)) (PRN (-LRB- -LRB-) (NP (NNS 3-months)) (-RRB- -RRB-)))) (PP (IN up) (PP (TO to) (NP (NP (JJ long-term) (NN progression)) (PRN (-LRB- -LRB-) (NP (JJ 21-months)) (-RRB- -RRB-)))))))))))))) (. .))
(S (NP (VBN Proposed) (NN model)) (VP (NNS combines) (NP (NP (NNS radiomics)) (CC and) (NP (JJ deep) (NN learning))) (S (VP (TO to) (VP (VB handle) (NP (NP (NNS challenges)) (VP (VBN related) (PP (TO to) (NP (NP (NP (VB imperfect) (NN ratio)) (PP (IN of) (NP (NNP OCT) (JJ scan) (NN dimension)))) (CC and) (NP (NN training) (NN cohort) (NN size)))))))))) (. .))
(S (NP (PRP We)) (VP (VBD considered) (NP (NP (DT a) (JJ retrospective) (JJ clinical) (NN trial) (NN dataset)) (SBAR (WHNP (WDT that)) (S (VP (VBZ includes) (NP (NP (CD 671) (JJ fellow) (NNS eyes)) (PP (IN with) (NP (CD 13,954) (JJ dry) (NNP AMD) (NNS observations))))))) (PP (IN for) (S (VP (NN training) (CC and) (VBG validating) (NP (DT the) (NN machine) (VBG learning) (NNS models)) (PP (IN on) (NP (DT a) (JJ 10-fold) (NN cross) (NN validation) (NN setting)))))))) (. .))
(S (NP (DT The) (VBN proposed) (NNP RNN) (NN model)) (VP (VP (VBD achieved) (NP (NP (JJ high) (NN accuracy)) (PRN (-LRB- -LRB-) (NP (CD 0.96) (NNP AUCROC)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (ADJP (DT both) (JJ short) (NN term) (CC and) (JJ long-term)) (NNP AMD) (NN progression))))))) (, ,) (CC and) (VP (VBD outperformed) (NP (NP (DT the) (JJ traditional) (NN random) (JJS forest) (NN model)) (VP (VBD trained))))) (. .))
(S (NP (NP (JJ High) (NN accuracy)) (VP (VBN achieved) (PP (IN by) (NP (DT the) (NNP RNN))))) (VP (VBZ establishes) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB identify) (NP (NP (NNP AMD) (NNS patients)) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (S (VP (VBG progressing) (PP (TO to) (NP (VB advanced) (NNP AMD))))))))) (PP (IN at) (NP (DT an) (JJ early) (NN stage)))))) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB have) (NP (DT a) (JJ high) (JJ clinical) (NN impact)) (SBAR (IN as) (S (NP (PRP it)) (VP (VBZ allows) (PP (IN for) (NP (NP (JJ optimal) (JJ clinical) (NN follow-up)) (, ,) (PP (IN with) (NP (NP (ADJP (RBR more) (JJ frequent)) (NN screening)) (CC and) (NP (NP (JJ potential) (RBR earlier) (NN treatment)) (PP (IN for) (NP (NP (DT those) (NNS patients)) (PP (IN at) (NP (JJ high) (NN risk))))))))))))))))))) (. .))
